Standard of care for colorectal cancer (CRC) patients to guide therapy selection involves tissue‐based genetic testing for at least three molecular biomarkers—RAS as a negative predictive marker for response to anti‐epithelial growth factor receptor (EGFR) antibodies; B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) as a negative prognostic marker and to predict response to the combination treatment with BRAF inhibitors and anti‐EGFR monoclonal antibodies; and microsatellite instability (MSI) status to evaluate the efficacy of immune‐checkpoint inhibitors [1]. This evidence concerns the gene BRAF and colorectal cancer.